CuraSen Therapeutics: Funding, Investors & Team (Sep 2026)
It's time to reconsider neurodegenerative disease treatments. At CuraSen, we use cutting-edge research and therapies to combat neurodegeneration so that patients may THINK, AGAIN. A privately funded biopharmaceutical business called CuraSen Therapeutics, Inc. is working to create novel medicines for a number of orphan indications as well as neurodegenerative disorders like Parkinson's and Alzheimer's. These illnesses afflict millions of patients and their families, and the numbers keep rising each year as the population ages. At CuraSen, we are developing a concept based on restoring a crucial capability to a route lost at an early stage in the degenerating brain in order to cure neurodegenerative illnesses.
CuraSen Therapeutics has raised $44.6M across 4 funding rounds on record, the most recent an undisclosed round of $5.8M announced in Sep 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CuraSen Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2024.
CuraSen Therapeutics Funding Rounds
CuraSen Therapeutics raised $18.0M in an undisclosed round announced in Nov 2021.
1 years later, an undisclosed round of $15.0M was announced in Nov 2022.
11 months later, an undisclosed round of $5.8M was announced in Oct 2023.
11 months later, an undisclosed round of $5.8M was announced in Sep 2024.
CuraSen Therapeutics Founders and Leadership Team
Contact details for the CuraSen Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →CuraSen Therapeutics Funding Compared to Other Biotechnology Startups
CuraSen Therapeutics' latest round of $5.8M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CuraSen Therapeutics in Biotechnology and San Carlos
Companies Similar to CuraSen Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
CuraSen Therapeutics Funding FAQs
What does CuraSen Therapeutics do?
It's time to reconsider neurodegenerative disease treatments. At CuraSen, we use cutting-edge research and therapies to combat neurodegeneration so that patients may THINK, AGAIN. A privately funded biopharmaceutical business called CuraSen Therapeutics, Inc. is working to create novel medicines for a number of orphan indications as well as neurodegenerative disorders like Parkinson's and Alzheimer's. These illnesses afflict millions of patients and their families, and the numbers keep rising each year as the population ages. At CuraSen, we are developing a concept based on restoring a crucial capability to a route lost at an early stage in the degenerating brain in order to cure neurodegenerative illnesses.
How much funding has CuraSen Therapeutics raised?
CuraSen Therapeutics has raised $44.6M across 4 rounds on record. The most recent is an undisclosed round of $5.8M announced in Sep 2024.
When did CuraSen Therapeutics last raise funding?
CuraSen Therapeutics' most recent funding round on record is an undisclosed round of $5.8M, announced in Sep 2024.
Who founded CuraSen Therapeutics?
FundedIQ lists Anthony P Ford (Founder), Kathleen Sereda Glaub (Founder) at CuraSen Therapeutics.
Where is CuraSen Therapeutics headquartered?
CuraSen Therapeutics is based in San Carlos, California, United States.
How many employees does CuraSen Therapeutics have?
CuraSen Therapeutics is in the 11-50 employee band.
How does CuraSen Therapeutics' funding compare to other Biotechnology startups?
CuraSen Therapeutics' latest round of $5.8M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's CuraSen Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CuraSen Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.